Fig. 2: Subgroup analysis of pathological complete response (pCR) by baseline factors (n = 136). | Nature Communications

Fig. 2: Subgroup analysis of pathological complete response (pCR) by baseline factors (n = 136).

From: Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial

Fig. 2

Data are presented as pCR rates (%) and 95% confidence intervals (CI). Black squares represent the differences in pCR rates between the ARX788 plus pyrotinib group and the TCbHP group across stratified subgroups. TCbHP, docetaxel plus carboplatin, trastuzumab and pertuzumab; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; FISH, fluorescence in situ hybridization; CI, confidence intervals. Source data are provided as Supplementary Table 1.

Back to article page